Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 5/2021

07.01.2021 | Review Article

Ivabradine in Cardiovascular Disease Management Revisited: a Review

verfasst von: Christopher Chen, Gurleen Kaur, Puja K. Mehta, Doralisa Morrone, Lucas C. Godoy, Sripal Bangalore, Mandeep S. Sidhu

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Ivabradine is a unique agent that is distinct from beta-blockers and calcium channel blockers as it reduces heart rate without affecting myocardial contractility or vascular tone. Ivabradine is a use-dependent inhibitor targeting the sinoatrial node. It is approved for use in the United States as an adjunct therapy for heart rate reduction in patients with heart failure with reduced ejection fraction. In this scenario, ivabradine has demonstrated improved clinical outcomes due to reduction in heart failure readmissions. However, there has been conflicting evidence from prospective studies and randomized controlled trials for its use in stable ischemic heart disease regarding efficacy in symptom reduction and mortality benefit. Ivabradine may also play a role in the treatment of patients with inappropriate sinus tachycardia, who often cannot tolerate beta-blockers and/or calcium channel blockers. In this review, we highlight the evidence for the nuances of using ivabradine in heart failure, stable ischemic heart disease, and inappropriate sinus tachycardia to raise awareness for its vital role in the treatment of select populations.
Literatur
1.
Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112:736–49.PubMedCrossRef
2.
Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987;113:1489–94.PubMedCrossRef
3.
Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 1991;121:172–7.PubMedCrossRef
4.
Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477–82.PubMedCrossRef
5.
Böhm M, Reil JC, Deedwania P, Kim JB, Borer JS. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. Am J Med. 2015;128:219–28.PubMedCrossRef
6.
Böhm M, Reil JC. Heart rate: surrogate or target in the management of heart failure? Heart. 2013;99:72–5.PubMedCrossRef
7.
Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823–30.PubMedCrossRef
8.
Tsuji H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996;94:2850–5.PubMedCrossRef
9.
Fragasso G, De Cobelli F, Spoladore R, et al. Resting cardiac energy metabolism is inversely associated with heart rate in healthy young adult men. Am Heart J. 2011;162:136–41.PubMedCrossRef
10.
Nathania M, Hollingsworth KG, Bates M, Eggett C, Trenell MI, Velicki L, et al. Impact of age on the association between cardiac high-energy phosphate metabolism and cardiac power in women. Heart. 2018;104:111–8.PubMedCrossRef
11.
Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70:1777–84.PubMedCrossRef
12.
Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2016;13:e136–221.PubMedCrossRef
13.
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.PubMedCrossRef
14.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–77.PubMedCrossRef
15.
Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov. 2011;10:903–14.PubMedCrossRef
16.
Baruscotti M, Bucchi A, Difrancesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther. 2005;107:59–79.PubMedCrossRef
17.
DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53:399–406.PubMedCrossRef
18.
DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine. Drugs. 2004;64:1757–65.PubMedCrossRef
19.
Thollon C, Bedut S, Villeneuve N, Cogé F, Piffard L, Guillaumin JP, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol. 2007;150:37–46.PubMedCrossRef
20.
Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120:1–13.PubMedPubMedCentralCrossRef
21.
Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J. 2004;25:579–86.PubMedCrossRef
22.
Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther. 2004;308:236–40.PubMedCrossRef
23.
Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–55.PubMedCrossRef
24.
Weeda ER, Nguyen E, White CM. Role of ivabradine in the treatment of patients with cardiovascular disease. Ann Pharmacother. 2016;50:475–85.PubMedCrossRef
25.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–9.PubMedCrossRef
26.
Núñez L, Crespo-Leiro MG, Marrón-Liñares GM, Suarez-Fuentetaja N, Barge-Caballero E, Paniagua-Martín MJ, et al. Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: a preliminary report. Cardiol J. 2016;23:573–82.PubMed
27.
Di Lullo L, Bellasi A, Russo D, et al. Ivabradine, heart failure and chronic kidney disease. Nephrol @ Point Care. 2015;1:poc.5000190.CrossRef
28.
Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441–6.PubMedCrossRef
29.
Spoladore R, Fragasso G, Perseghin G, de Cobelli F, Esposito A, Maranta F, et al. Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. Fundam Clin Pharmacol. 2013;27:455–64.PubMedCrossRef
30.
Valentini M, Parati G. Variables influencing heart rate. Prog Cardiovasc Dis. 2009;52:11–9.PubMedCrossRef
31.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.PubMedCrossRef
32.
Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100:1506–10.PubMedCrossRef
33.
Camm AJ, Lau C-P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003;4:83–9.PubMedCrossRef
34.
López-Bescós L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108:387–96.PubMedCrossRef
35.
Demontis GC, Longoni B, Barcaro U, Cervetto L. Properties and functional roles of hyperpolarization-gated currents in guinea-pig retinal rods. J Physiol. 1999;515:813–28.PubMedPubMedCentralCrossRef
36.
Satoh T-O, Yamada M. A bradycardiac agent ZD7288 blocks the hyperpolarization-activated current (Ih) in retinal rod photoreceptors. Neuropharmacology. 2000;39:1284–91.PubMedCrossRef
37.
Cervetto L, Demontis GC, Gargini C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol. 2007;150:383–90.PubMedPubMedCentralCrossRef
38.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRef
39.
Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.PubMedCrossRef
40.
McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–94.PubMedCrossRef
41.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e61.PubMedCrossRef
42.
Bozkurt B. What is new in heart failure management in 2017? Update on ACC/AHA Heart Failure Guidelines. Curr Cardiol Rep. 2018;20:39.PubMedCrossRef
43.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.PubMedCrossRef
44.
Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33:2813–20.PubMedPubMedCentralCrossRef
45.
Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11–22.PubMedCrossRef
46.
Böhm M, Robertson M, Ford I, Borer JS, Komajda M, Kindermann I, et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with Ivabradine in stable heart failure (from the SHIFT trial). Am J Cardiol. 2015;116:1890–7.PubMedCrossRef
47.
Bocchi EA, Böhm M, Borer JS, Ford I, Komajda M, Swedberg K, et al. Effect of combining ivabradine and β-blockers: focus on the use of carvedilol in the SHIFT population. Cardiology. 2015;131:218–24.PubMedCrossRef
48.
Komajda M, Böhm M, Borer J, Ford I, Krum H, Tase A, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. Eur J Heart Fail. 2013;15:79–84.PubMedCrossRef
49.
Böhm M, Komajda M, Borer JS, Ford I, Maack C, Tavazzi L, et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail. 2018;20:373–81.PubMedCrossRef
50.
Borer JS, Swedberg K, Komajda M, Ford I, Tavazzi L, Böhm M, et al. Efficacy profile of Ivabradine in patients with heart failure plus angina pectoris. Cardiology. 2017;136:138–44.PubMedCrossRef
51.
Komajda M, Böhm M, Borer JS, Ford I, Robertson M, Manolis AJ, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014;16:810–6.PubMedCrossRef
52.
Tardif JC, O'Meara E, Komajda M, Böhm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–15.PubMedPubMedCentralCrossRef
53.
Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62:1977–85.PubMedCrossRef
54.
Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395–404.PubMedCrossRef
55.
Bouabdallaoui N, O'Meara E, Bernier V, Komajda M, Swedberg K, Tavazzi L, et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Fail. 2019;6:1199–207.PubMedPubMedCentralCrossRef
56.
Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, et al. Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure. Int Heart J. 2019;60:899–909.PubMedCrossRef
57.
Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (systolic heart failure treatment with the I(f) inhibitor ivabradine trial) study. J Am Coll Cardiol. 2012;59:1938–45.PubMedCrossRef
58.
Psotka MA, Teerlink JR. Ivabradine: role in the chronic heart failure armamentarium. Circulation. 2016;133:2066–75.PubMedCrossRef
59.
Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013;15:1296–303.PubMedCrossRef
60.
Hidalgo FJ, Anguita M, Castillo JC, Rodríguez S, Pardo L, Durán E, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol. 2016;217:7–11.PubMedCrossRef
61.
Mentz RJ, DeVore AD, Tasissa G, et al. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: results of the PRIME-HF trial. Am Heart J. 2020;223:98–105.PubMedCrossRef
62.
Sarraf M, Francis GS. It is all about heart rate. Or is it? J Am Coll Cardiol. 2012;59:1946–7.PubMedCrossRef
63.
Tondi L, Fragasso G, Spoladore R, Pinto G, Gemma M, Slavich M, et al. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. J Cardiovasc Med (Hagerstown). 2018;19:351–6.CrossRef
64.
Das D, Savarese G, Dahlström U, Fu M, Howlett J, Ezekowitz JA, et al. Ivabradine in heart failure: the representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a broad population of patients with chronic heart failure. Circ Heart Fail. 2017;10:e004112.PubMedCrossRef
65.
Cullington D, Goode KM, Cleland JG, Clark AL. Limited role for ivabradine in the treatment of chronic heart failure. Heart. 2011;97:1961–6.PubMedCrossRef
66.
Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of if-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330–8.PubMedCrossRef
67.
Pal N, Sivaswamy N, Mahmod M, Yavari A, Rudd A, Singh S, et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015;132:1719–25.PubMedPubMedCentralCrossRef
68.
Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495–503.PubMedCrossRef
69.
Nadeem M, Hassib M, Aslam HM, Fatima D, Illahi Y. Role of ivabradine in patients with heart failure with preserved ejection fraction. Cureus. 2020;12:e7123.PubMedPubMedCentral
70.
Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–23.PubMedCrossRef
71.
Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–36.PubMedCrossRef
72.
Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540–8.PubMedPubMedCentralCrossRef
73.
Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393–405.PubMedCrossRef
74.
Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.PubMedCrossRef
75.
76.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337–45.PubMedCrossRef
77.
Fox K, Ford I, Steg PG, et al. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166:654–61.e6.PubMedCrossRef
78.
McMurray JJ. It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? Eur Heart J. 2015;36:2047–9.PubMedCrossRef
79.
Ferrari R, Fox KM. The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. Eur Heart J. 2015;36:2042–6.PubMedCrossRef
80.
Rimoldi SF, Messerli FH, Cerny D, Gloekler S, Traupe T, Laurent S, et al. Selective heart rate reduction with ivabradine increases central blood pressure in stable coronary artery disease. Hypertension. 2016;67:1205–10.PubMedCrossRef
81.
Messerli FH, Rimoldi SF, Bangalore S, Bavishi C, Laurent S. When an increase in central systolic pressure overrides the benefits of heart rate lowering. J Am Coll Cardiol. 2016;68:754–62.PubMedCrossRef
82.
Mengesha HG, Weldearegawi B, Petrucka P, Bekele T, Otieno MG, Hailu A. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials. BMC Cardiovasc Disord. 2017;17:105.PubMedPubMedCentralCrossRef
83.
Cammarano C, Silva M, Comee M, Donovan JL, Malloy MJ. Meta-analysis of Ivabradine in patients with stable coronary artery disease with and without left ventricular dysfunction. Clin Ther. 2016;38:387–95.PubMedCrossRef
84.
Zarifis J, Kallistratos M, Katsivas A. Antianginal efficacy of ivabradine/metoprolol combination in patients with stable angina. Clin Cardiol. 2016;39:697–702.PubMedPubMedCentralCrossRef
85.
Glezer M, Vasyuk Y, Karpov Y. Efficacy of ivabradine in combination with beta-blockers versus uptitration of beta-blockers in patients with stable angina (CONTROL-2 study). Adv Ther. 2018;35:341–52.PubMedPubMedCentralCrossRef
86.
Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101:365–73.PubMedCrossRef
87.
Dillinger JG, Maher V, Vitale C, Henry P, Logeart D, Manzo Silberman S, et al. Impact of Ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease. Hypertension. 2015;66:1138–44.PubMedCrossRef
88.
Camici GG, Savarese G, Akhmedov A, Luscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J. 2015;36:3392–403.PubMedCrossRef
89.
Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12:e41–63.PubMedPubMedCentralCrossRef
90.
Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323–9.PubMedCrossRef
91.
BENEZET-MAZUECOS J, Rubio JM, Farré J, et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol. 2013;36:830–6.PubMedCrossRef
92.
Kaczmarek K, Klingenheben T, Poddebska I, Urbanek I, Wranicz JK, Cygankiewicz I, et al. Baseline intrinsic heart rate and response to ivabradine treatment in patients with inappropriate sinus tachycardia. Ann Noninvasive Electrocardiol. 2020;25:e12709.PubMedCrossRef
93.
Calò L, Rebecchi M, Sette A, Martino A, de Ruvo E, Sciarra L, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318–23.PubMedCrossRef
94.
Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2012;15:116–21.PubMedCrossRef
95.
Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, Wranicz JK. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338–44.PubMedCrossRef
96.
Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia–symptom and heart rate reduction with ivabradine: a pooled analysis of prospective studies. Heart Rhythm. 2018;15:240–7.PubMedCrossRef
97.
Annamaria M, Lupo PP, Foresti S, de Ambroggi G, de Ruvo E, Sciarra L, et al. Treatment of inappropriate sinus tachycardia with ivabradine. J Interv Card Electrophysiol. 2016;46:47–53.PubMedCrossRef
Metadaten
Titel
Ivabradine in Cardiovascular Disease Management Revisited: a Review
verfasst von
Christopher Chen
Gurleen Kaur
Puja K. Mehta
Doralisa Morrone
Lucas C. Godoy
Sripal Bangalore
Mandeep S. Sidhu
Publikationsdatum
07.01.2021
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5/2021
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-020-07124-4

Weitere Artikel der Ausgabe 5/2021

Cardiovascular Drugs and Therapy 5/2021 Zur Ausgabe

Original Article

Strategies to Reduce Out-of-Pocket Medication Costs for Canadians Living with Heart Failure

Original Article

Impact of Peripheral α7-Nicotinic Acetylcholine Receptors on Cardioprotective Effects of Donepezil in Chronic Heart Failure Rats

Original Article

Extracellular Vesicles Derived from Intermittent Hypoxia–Treated Red Blood Cells Impair Endothelial Function Through Regulating eNOS Phosphorylation and ET-1 Expression

Original Article

Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy

Original Article

Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis

Original Article

Methotrexate Therapy Promotes Cell Coverage and Stability in in-Stent Neointima

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise